Is Europe’s PRIME program meeting its objectives?

Since the PRiority MEdicines (PRIME) program scheme was introduced two years ago, more than 40 products have been granted PRIME designation.1  In August 2018, the first two therapies with PRIME designation were granted marketing approval by the European Commission (EC) – Novartis’s Kymriah (tisagenlecleucel) and Kite Pharma/Gilead’s Yescarta (axicabtagene ciloleucel). Yescarta and Kymriah are both […]

European biotech on course for record year with $3.9B raised in first half of 2018

This is the second of a two-part series on Life Sciences Connect looking at the current robust financial climate for biopharma. “Biopharma IPOs gone wild,” also via BioWorld, the daily biopharma news service from Clarivate Analytics, appeared on July 10, 2018. European biotechnology firms engaged in drug development raised $3,904 million during the first half […]

For 2018, Europe’s top 100 most innovative universities

Using data from Clarivate Analytics, Reuters has updated its annual presentation of the world’s most innovative institutions. This installment covers European universities. The new listing of Europe’s top 100, like the rankings in each of the two previous years, is based on publication and patent figures supplied by Clarivate. These data points specify the institutions […]

Paying for Performance: EFPIA’s Catch-22 for European Drug Pricing

A leaked internal paper could signal a tidal shift in European drug pricing as companies and payers continue their combined march toward value-based pricing. However, the concession by industry could come at a price to payers, namely their reliance on cost containment measures such as external reference pricing, which suggests that this roadmap is just […]